Brendan McAtamney
LAST YEAR it was almost impossible to decipher the results for UDG Healthcare (previously United Drug) and, this year, the damage done to the group by a disastrous sell-off has again been well disguised. There are serious questions to be asked about the sale of UDG’s Aquilant subsidiary, which resulted in a loss of $100m.... Read more »
To access this content, you must be a Phoenix subscriber.
Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!
